Clinical Trial Results:
            A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH LOW- OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH A DELETION (DEL) 5Q[31] CYTOGENETIC ABNORMALITY
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2005-000454-73 | 
    Trial protocol  | 
        GB SE DE ES IT BE | 
    Global completion date  | 
        
                                    09 Jul 2013
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v2(current) | 
    This version publication date  | 
        
                                    17 Nov 2016
                             
         | 
    
    First version publication date  | 
        
                                    20 Apr 2016
                             
         | 
    
    Other versions  | 
        v1 | 
    Version creation reason  | 
        
  | 
    
    Summary report(s)  | 
                                CSR Synopsis CC-5013-mds-004-synop-rreport-follow-up  | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.